Category
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Today's News
More News
Clinical trial shows tumor-starving drug improves survival of mesothelioma

Clinical trial shows tumor-starving drug improves survival of mesothelioma

byQueen Mary, University of LondonPeter Szlosarek. Credit: Queen Mary, University of LondonPeter Szlosarek, Professor of Medical Oncology at Queen Mary's Barts Cancer Institute, presented hi

Clinical trial shows tumor-starving drug improves survival of mesothelioma

byQueen Mary, University of LondonPeter Szlosarek. Credit: Queen Mary, University of LondonPeter Szlosarek, Professor of Medical Oncology at Queen Mary's Barts Cancer Institute, presented hi
Clinical trial shows promising results for patients with advanced neuroendocrine tumors

Clinical trial shows promising results for patients with advanced neuroendocrine tumors

by Alliance for Clinical Trials in OncologyCredit: Pixabay/CC0 Public DomainThe Alliance for Clinical Trials in Oncology today announced that an independent Data and Safety Monitoring Board (DSMB) det

Clinical trial shows promising results for patients with advanced neuroendocrine tumors

by Alliance for Clinical Trials in OncologyCredit: Pixabay/CC0 Public DomainThe Alliance for Clinical Trials in Oncology today announced that an independent Data and Safety Monitoring Board (DSMB) det
Clinical trial: Three-drug combination slows progression of advanced kidney cancer

Clinical trial: Three-drug combination slows progression of advanced kidney cancer

byDana-Farber Cancer InstituteCredit: Pixabay/CC0 Public DomainA targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previ

Clinical trial: Three-drug combination slows progression of advanced kidney cancer

byDana-Farber Cancer InstituteCredit: Pixabay/CC0 Public DomainA targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previ
Clinical trial: Immunotherapy strongly improves prognosis of babies with leukemia

Clinical trial: Immunotherapy strongly improves prognosis of babies with leukemia

by Princess Máxima Center for Pediatric OncologyCredit: Unsplash/CC0 Public DomainImmunotherapy with blinatumomab leads to a strongly improved survival rate—from 66% to 93%—for children with an aggres

Clinical trial: Immunotherapy strongly improves prognosis of babies with leukemia

by Princess Máxima Center for Pediatric OncologyCredit: Unsplash/CC0 Public DomainImmunotherapy with blinatumomab leads to a strongly improved survival rate—from 66% to 93%—for children with an aggres
Clinical trial: Combination treatment extends progression-free survival in brain cancer

Clinical trial: Combination treatment extends progression-free survival in brain cancer

by Melissa Rohman,Northwestern UniversityCredit: Pixabay/CC0 Public DomainRepeat radiation therapy combined with the monoclonal antibody drug bevacizumab extended progression-free survival in pa

Clinical trial: Combination treatment extends progression-free survival in brain cancer

by Melissa Rohman,Northwestern UniversityCredit: Pixabay/CC0 Public DomainRepeat radiation therapy combined with the monoclonal antibody drug bevacizumab extended progression-free survival in pa
Clinical trial: Extended lymph node removal does not benefit patients with localized muscle-invasive bladder cancer

Clinical trial: Extended lymph node removal does not benefit patients with localized muscle-invasive bladder cancer

by SWOG Cancer Research NetworkCredit: Pixabay/CC0 Public DomainAn extended lymphadenectomy—removal of additional lymph nodes beyond the extent of the standard procedure—in patients undergoing radical

Clinical trial: Extended lymph node removal does not benefit patients with localized muscle-invasive bladder cancer

by SWOG Cancer Research NetworkCredit: Pixabay/CC0 Public DomainAn extended lymphadenectomy—removal of additional lymph nodes beyond the extent of the standard procedure—in patients undergoing radical
Clinical trial: Adding EBRT to brachytherapy does not improve outcomes for men with intermediate-risk prostate cancer

Clinical trial: Adding EBRT to brachytherapy does not improve outcomes for men with intermediate-risk prostate cancer

by NRG OncologyCredit: Unsplash/CC0 Public DomainResults from the NRG Oncology NRG-RTOG 0232 clinical trial adding external beam radiotherapy (EBRT) to brachytherapy (BT) in men with intermediate-risk

Clinical trial: Adding EBRT to brachytherapy does not improve outcomes for men with intermediate-risk prostate cancer

by NRG OncologyCredit: Unsplash/CC0 Public DomainResults from the NRG Oncology NRG-RTOG 0232 clinical trial adding external beam radiotherapy (EBRT) to brachytherapy (BT) in men with intermediate-risk
Clinical trial improves neurocognitive outcomes for childhood craniopharyngioma

Clinical trial improves neurocognitive outcomes for childhood craniopharyngioma

bySt. Jude Children's Research HospitalPrincipal investigator Thomas Merchant, D.O., Ph.D., St. Jude Radiation Oncology chair, standing by the beam line of the St. Jude Proton Therapy Center

Clinical trial improves neurocognitive outcomes for childhood craniopharyngioma

bySt. Jude Children's Research HospitalPrincipal investigator Thomas Merchant, D.O., Ph.D., St. Jude Radiation Oncology chair, standing by the beam line of the St. Jude Proton Therapy Center
Radiotherapy boost can cut breast cancer treatment time by at least one week, finds clinical trial

Radiotherapy boost can cut breast cancer treatment time by at least one week, finds clinical trial

by Craig Brierley,University of CambridgeCredit: Pixabay/CC0 Public DomainTreatment times for radiotherapy could be reduced for some early breast cancer patients, according to a trial led by Uni

Radiotherapy boost can cut breast cancer treatment time by at least one week, finds clinical trial

by Craig Brierley,University of CambridgeCredit: Pixabay/CC0 Public DomainTreatment times for radiotherapy could be reduced for some early breast cancer patients, according to a trial led by Uni
Immunotherapy for 'difficult to treat' lung cancer patients improves long-term survival: Clinical trial

Immunotherapy for 'difficult to treat' lung cancer patients improves long-term survival: Clinical trial

byUniversity College LondonCredit: Pixabay/CC0 Public DomainA global study, led by UCL and UCLH, has shown that the cancer immunotherapy atezolizumab significantly improved the overall survival

Immunotherapy for 'difficult to treat' lung cancer patients improves long-term survival: Clinical trial

byUniversity College LondonCredit: Pixabay/CC0 Public DomainA global study, led by UCL and UCLH, has shown that the cancer immunotherapy atezolizumab significantly improved the overall survival
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...